# US 2023/0066136 A1 · Compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0066136 A1
- Document ID: US20230066136A1
- Status: Published application
- Kind: A1
- Application number: 17/425,153
- Filed: 2020-01-29
- Published: 2023-03-02
- Earliest claimed: 2019-01-29
- Assignees: Foghorn Therapeutics Inc.
- Applicants: Foghorn Therapeutics Inc.
- Inventors: Sabine K. RUPPEL; Zhaoxia YANG; Jason T. LOWE; Johannes H. VOIGT; Matthew NETHERTON
- Web page: https://patentgrep.com/patent/US20230066136A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- C07D 401/14: containing three or more hetero rings
- C07D 471/10: Spiro-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 487/10: Spiro-condensed systems
- C07D 498/10: Spiro-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compositions and methods for the treatment of BAF-related disorders, such as cancers and viral infections.

## Claims

### Claim 1

A compound having the structure of Formula I:
A-L-B Formula I,
wherein
A is
wherein
A1 is a bond between A and L;
R4 is H, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C1-C6 heteroalkyl, or optionally substituted C3-C10 carbocyclyl
R5 is H, halogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C3-C10 carbocyclyl, or optionally substituted C6-C10 aryl;
R6a is H, halogen, cyano, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C3-C10 carbocyclyl, optionally substituted C2-C9 heterocyclyl, optionally substituted C6-C10 aryl, optionally substituted C2-C9 heteroaryl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 heteroalkenyl, hydroxy, thiol, or optionally substituted amino;
R6b is H, halogen, cyano, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C3-C10 carbocyclyl, optionally substituted C2-C9 heterocyclyl, optionally substituted C6-C10 aryl, optionally substituted C2-C9 heteroaryl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 heteroalkenyl, hydroxy, thiol, or optionally substituted amino, or R6a and R6b, together with the carbon atoms to which each is attached, combine to form optionally substituted C6-C10 aryl or optionally substituted C2-C9 heteroaryl;
B is
wherein
A2 is a bond between B and L;
v1 is 0, 1, 2, 3, 4, or 5;
RA5 is H, optionally substituted C1-C5 alkyl, or optionally substituted C1-C5 heteroalkyl;
each RJ1 is, independently, halogen, optionally substituted C1-C6 alkyl, or optionally substituted C1-C6 heteroalkyl;
JA is absent, O, optionally substituted amino, optionally substituted C1-C5 alkyl, or optionally substituted C1-C6 heteroalkyl; and
J is absent, optionally substituted C3-C10 carbocyclylene, optionally substituted C6-C10 arylene, optionally substituted C2-C9 heterocyclylene, or optionally substituted C2-C9 heteroarylene, optionally substituted amino, optionally substituted C1-C6 alkyl, or optionally substituted C1-C6 heteroalkyl; and
L is
A1-(E1)-(F1)—(C3)m-(F2)o1-A2, Formula IId
wherein
A1 is a bond between L and A;
A2 is a bond between B and L;
each of m and o1 is, independently, 0 or 1;
O, S, NRN, optionally substituted C1-10 alkylene, optionally substituted C2-10 alkenylene, optionally substituted C2-10 alkynylene, optionally substituted C2-C10 polyethylene glycol, or optionally substituted C1-10 heteroalkylene;
RN is H, optionally substituted C1-4 alkyl, optionally substituted C2-4 alkenyl, optionally substituted C2-4 alkynyl, optionally substituted C2-6 heterocyclyl, optionally substituted C6-12 aryl, or optionally substituted C1-7 heteroalkyl;
C3 is carbonyl, thiocarbonyl, sulphonyl, or phosphoryl; and
each of F1 and F2 is, independently, optionally substituted C3-C10 carbocyclylene, optionally substituted C2-10 heterocyclylene, optionally substituted C6-C10 arylene, or optionally substituted C2-C9 heteroarylene,
or a pharmaceutically acceptable salt thereof.

### Claim at position 2

2-17. (canceled)

### Claim 18 (depends on 1)

The compound of claim 1, wherein E1 is
where a is 0, 1, 2, 3, 4, or 5.

### Claim 19

(canceled)

### Claim 20 (depends on 18)

The compound of claim 18, wherein E1 is

### Claim at position 6

21-30. (canceled)

### Claim 31 (depends on 1)

The compound of claim 1, wherein each of F1 and F2 is, independently, optionally substituted C3-C10 carbocyclylene.

### Claim at position 8

32-38. (canceled)

### Claim 39 (depends on 1)

The compound of claim 1, wherein each of F1 and F2 is, independently, optionally substituted C2-C6 heterocyclylene.

### Claim 40

(canceled)

### Claim 41 (depends on 39)

The compound of claim 39, wherein the C2-C6 heterocyclylene is
wherein
q1 is 0, 1, 2, 3, or 4;
q2 is 0, 1, 2, 3, 4, 5, or 6;
q3 is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
each Rh is, independently, 2H, halogen, optionally substituted C1-C6 alkyl, ORi2, or NRi3Ri4; or two Rh groups, together with the carbon atom to which each is attached, combine to form optionally substituted C3-C10 carbocyclyl or optionally substituted C2-C9 heterocyclyl; or two Rh groups, together with the carbon atoms to which each is attached, combine to form optionally substituted C3-C10 carbocyclyl or optionally substituted C2-C9 heterocyclyl;
Ri1 is H or optionally substituted C1-C6 alkyl;
Ri2 is H, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, or optionally substituted C3-C6 carbocyclyl;

### Claim at position 12

42-50. (canceled)

### Claim 51 (depends on 39)

The compound of claim 39, wherein each of F1 and F2 is, independently,

### Claim 52 (depends on 39)

The compound of claim 39, wherein F1 is

### Claim 53 (depends on 39)

The compound of claim 39, wherein F2 is

### Claim at position 16

54-77. (canceled)

### Claim 78 (depends on 1)

The compound of claim 1, wherein m is 0.

### Claim at position 18

79-80. (canceled)

### Claim 81 (depends on 1)

The compound of claim 1, wherein o1 is 1.

### Claim at position 20

82-116. (canceled)

### Claim 117 (depends on 1)

The compound of claim 1, wherein v1 is 0.

### Claim at position 22

118-119. (canceled)

### Claim 120 (depends on 1)

The compound of claim 1, wherein RA5 is H.

### Claim at position 24

121-128. (canceled)

### Claim 129 (depends on 1)

The compound of claim 1, wherein J is optionally substituted C3-C10 carbocyclylene or optionally substituted C6-C10 arylene.

### Claim at position 26

130-186. (canceled)

### Claim 187 (depends on 1)

The compound of claim 1, wherein R4 is H.

### Claim at position 28

188-199. (canceled)

### Claim 200 (depends on 1)

The compound of claim 1, wherein R5 is H,

### Claim 201 (depends on 200)

The compound of claim 200, wherein R5 is H or

### Claim at position 31

202-204. (canceled)

### Claim 205 (depends on 1)

The compound of claim 1, wherein R8a is H, F, cyano,

### Claim at position 33

206-208. (canceled)

### Claim 209 (depends on 1)

The compound of claim 1, wherein R6b is H, F, cyano,

### Claim at position 35

210-300. (canceled)

### Claim 301

A compound having the structure of any one of compounds D1-D259 in Table 1A, D260-D371 in Table 1B, D372-D476 in Table 1D, DD1-DD10 in Table 1C, and DD11-DD16 in Table 1E.

### Claim at position 37

302-305. (canceled)

### Claim 306 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim 307 (depends on 1)

A method of inhibiting the level or activity of BRD9 in a cell, the method involving contacting the cell with an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 308

(canceled)

### Claim 309 (depends on 307)

The method of claim 307, wherein the cell is a cancer cell.

### Claim 310 (depends on 309)

The method of claim 309, wherein the cancer is a malignant, rhabdoid tumor, a CD8+ T-cell lymphoma, endometrial carcinoma, ovarian carcinoma, bladder cancer, stomach cancer, pancreatic cancer, esophageal cancer, prostate cancer, renal cell carcinoma, melanoma, colorectal cancer, a sarcoma, non-small cell lung cancer, stomach cancer, or breast cancer.

### Claim 311 (depends on 310)

The method of claim 310, wherein the cancer is a sarcoma.

### Claim 312

(canceled)

### Claim 313 (depends on 311)

The method of claim 311, wherein the sarcoma is synovial sarcoma.

### Claim 314 (depends on 1)

A method of treating a BAF complex-related disorder, an SS18-SSX fusion protein-related disorder, or a BRD9-related disorder in a subject in need thereof, the method involving administering to the subject an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim at position 47

315-317. (canceled)

### Claim 318 (depends on 1)

A method of treating a cancer in a subject in need thereof, the method including administering to the subject an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 319

(canceled)

### Claim 320 (depends on 318)

The method of claim 318, wherein the cancer is a sarcoma.

### Claim 321

(canceled)

### Claim 322 (depends on 320)

The method of claim 320, wherein the sarcoma is synovial sarcoma.

### Claim 323

(canceled)

### Claim 324 (depends on 1)

A method of treating infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim at position 55

325-327. (canceled)

### Claim 328 (depends on 20)

The compound of claim 20, wherein
each of R4, R6a, and R6b is
R5 is H;
v1 is 0;
RA5 is H;
JA is amino;
J is optionally substituted C6-C10 arylene;
m is 0;
o1 is 1;
F1 is
and
F2 is
